



Iron Salt Drugs

Monoferric (ferric derisomaltose) J1437, Feraheme (ferumoxytol) Q0138, Q0139, Injectafer (ferric carboxymaltose) J1439, Triferic (ferric pyrophosphate) J1443 are Non-preferred products. The preferred products are: Infed (iron dextran) J1750, Venofer (iron sucrose) J1756, Ferrlecit (sodium ferric gluconate cmplx) J2916
Prior Authorization Request
Medicare Part B Form

*Instructions: * Indicates required information – Form may be returned if required information is not provided. Please fax this request to the appropriate fax number listed at the bottom of the page.*

| | | | |
|--|-------------------------------------|--------------------------|--|
| <input type="checkbox"/> | Standard Request– (72 Hours) | <input type="checkbox"/> | Urgent Request (standard time frame could place the member's life, health or ability in serious jeopardy) |
| Date Requested _____ | | | |
| Requestor _____ Clinic name: _____ Phone _____ / Fax _____ | | | |

MEMBER INFORMATION

*Name: _____ *ID#: _____ *DOB: _____

PRESCRIBER INFORMATION

*Name: _____ MD FNP DO NP PA *Phone: _____

*Address: _____ *Fax: _____

DISPENSING PROVIDER / ADMINISTRATION INFORMATION

*Name: _____ Phone: _____

*Address: _____ Fax: _____

PROCEDURE / PRODUCT INFORMATION

| HCCP Code | Name of Drug | Dose (Wt: _____ kg Ht: _____) | Frequency | End Date if known |
|-----------|--------------|--------------------------------|-----------|-------------------|
| | | | | |

Self-administered Provider-administered Home Infusion

Chart notes attached. **Other important information:** _____

Diagnosis: ICD10: _____ **Description:** _____

Provider attests the diagnosis provided is an FDA-Approved indication for this drug

CLINICAL INFORMATION

New Start or Initial Request: (Clinical documentation required for all requests)

Patient has a diagnosis of chronic kidney disease (CKD); AND

- Patient is dialysis dependent; AND
- Patient has iron deficiency anemia (IDA);

Patient has a diagnosis of iron deficiency anemia (IDA); AND

- Patient is non-dialysis dependent;
- Diagnosis is confirmed by one of the following:
 - For IDA associated with CKD or inflammatory conditions (for example, inflammatory bowel disease [IBD], heart failure), Patient meets one of the following within the last four (4) weeks:
 - Serum ferritin levels less than 100 ng/mL; OR
 - TSAT levels less than 20%; OR

- Serum ferritin is less than or equal to 500 ng/mL and TSAT is less than or equal to 30% OR
 - Bone marrow demonstrates inadequate iron stores; OR
 - Hemoglobin (HGB) less than 13 g/dl (less than 130 g/l) in males or less than 12 g/dl (less than 120g/l) in females and TSAT 30% or less and ferritin 500ng/ml or less (500 µg/l or less) (Ko 2020);
 - For IDA associated with cancer/chemotherapy or non-inflammatory conditions (for example, blood loss, malabsorption, malnutrition), Patient meets one of the following within the last four (4) weeks:
 - Serum ferritin levels less than 30 ng/mL; OR
 - TSAT levels less than 20%; OR
 - Bone marrow demonstrates inadequate iron stores; AND
 - Patient had a four (4) week trial of and inadequate response, or intolerance to oral iron supplementation; OR
 - Patient is unable to use oral iron supplementation for one of the following reasons:
 - Malabsorption conditions; OR
 - Gastric Surgery;
 - Patient has iron deficiency anemia in pregnancy;
 - Diagnosis is confirmed by one of the following:
 - Serum ferritin levels less than 30 ng/mL; OR
 - TSAT levels less than 20%; OR
 - Bone marrow demonstrates inadequate iron stores; AND
 - Patient is past 14 weeks of pregnancy and has had a four (4) week trial of and inadequate response, or intolerance to oral iron supplementation (Muñoz 2017); OR
 - Patient is past 14 weeks of pregnancy and diagnosed with severe iron deficiency anemia, defined as Hemoglobin (HGB) less than 8 g/dL; OR
 - Patient is past 34 weeks of pregnancy.
- If not, please provide **clinical rationale** for formulary exception: _____

- Continuation Requests: (Clinical documentation required for all requests)
 - Patient had an adequate response or significant improvement while on this medication.
 If not, please provide clinical rationale for continuing this medication: _____

ACKNOWLEDGEMENT

Request By (Signature Required): _____ **Date:** ____ / ____ / ____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties. **THIS AUTHORIZATION IS NOT A GUARANTEE OF PAYMENT.** PAYMENT IS BASED ON BENEFITS IN EFFECT AT THE TIME OF SERVICE, MEMBER ELIGIBILITY AND MEDICAL NECESSITY.

Prior Authorization Group – Iron Salt Drugs PA

Drug Name(s):

| | |
|------------|-----------------------|
| FERAHEME | FERUMOXYTOL |
| INJECTAFER | FERRIC CARBOXYMALTOSE |
| TRIFERIC | FERRIC PYROPHOSPHATE |
| MONOFERRIC | DERISOMALTOSE |
| INFED | IRON DEXTRAM |
| VENOFER | IRON SUCROSE |

Criteria for approval of Prior Authorization Drug:

1. Prescribed for an approved FDA diagnosis (as listed below):
2. Member does not have any clinically relevant contraindications, or CMS/Plan exclusions, to the requested drug.
 - If the member meets all these criteria, they may be approved by the Plan for the requested drug.
 - Quantity limits and Tiering will be determined by the Plan.

Exclusion Criteria:

N/A

Prescriber Restrictions:

N/A

Coverage Duration:

Approvals will be for 12 months

FDA Indications:

Feraheme, Injectafer, Venofer, InFed, Monoferric

- Chronic kidney disease - Iron deficiency anemia (Injectafer: only for nondialysis dependent)
- Iron deficiency anemia, Intolerant or unsatisfactory response to oral iron

Triferic

- Dependence on hemodialysis due to end stage renal disease - Iron deficiency anemia

Off-Label Uses:

Injectafer

- Iron deficiency anemia of pregnancy

Age Restrictions:

Safety and efficacy have not been established in pediatric patients

Other Clinical Considerations:

N/A

Resources:

https://www.micromedexsolutions.com/micromedex2/librarian/CS/5995F8/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/7ED93E/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.DoIntegratedSearch?SearchTerm=Ferumoxytol&UserSearchTerm=FerumoxytoI&SearchFilter=filterNone&navitem=searchGlobal#

https://www.micromedexsolutions.com/micromedex2/librarian/CS/8D753E/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/733967/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.DoIntegratedSearch?SearchTerm=ferric%20carboxymaltose&UserSearchTerm=ferric%20carboxymaltose&SearchFilter=filterNone&navitem=searchGlobal#

https://www.micromedexsolutions.com/micromedex2/librarian/CS/49B55F/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/5AA0F0/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.GoToDashboard?docId=931341&contentSetId=100&title=Ferric+Pyrophosphate+Citrate&servicesTitle=Ferric+Pyrophosphate+Citrate&brandName=Triferic&UserMdxSearchTerm=TRIFERIC&=null#

https://www.micromedexsolutions.com/micromedex2/librarian/CS/0012A4/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/55818C/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.GoToDashboard?docId=932812&contentSetId=100&title=Ferric+Derisomalto se&servicesTitle=Ferric+Derisomalto se&brandName=Monoferric&UserMdxSearchTerm=monoferric&=null#

https://www.micromedexsolutions.com/micromedex2/librarian/CS/687EE7/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/98A6CB/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.GoToDashboard?docId=304970&contentSetId=100&title=Iron+Dextran&servicesTitle=Iron+Dextran&brandName=Infed&UserMdxSearchTerm=Infed&=null#

https://www.micromedexsolutions.com/micromedex2/librarian/CS/7FC1A8/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/1D7DA4/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.GoToDashboard?docId=925477&contentSetId=100&title=Iron+Sucrose&servicesTitle=Iron+Sucrose&brandName=PremierPro+Rx+Venofer&UserMdxSearchTerm=Venofer&=null#

CLINICAL ONLY